Advertisement

Reactions Weekly

, Volume 1734, Issue 1, pp 84–84 | Cite as

Bevacizumab/erlotinib

Acquired resistance during lung cancer with leptomeningeal metastases: case report
Case report
  • 11 Downloads

Reference

  1. Tsuchiya K, et al. An acquired epidermal growth factor receptor t790m mutation after the addition of bevacizumab to preceding erlotinib monotherapy in a lung cancer patient with leptomeningeal metastases. Internal Medicine 57: 3423-3427, No. 23, 2018. Available from: URL: https://doi.org/10.2169/internalmedicine.1062-18 - JapanCrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations